Can Biçmen

Can Biçmen

Auto-generated profile, based on publicly available information

Can Biçmen

University of Health Sciences Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, Izmir, Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
CÇCengi̇z Çavuşoğlu
Cengi̇z Çavuşoğlu
MÇMuhsi̇n Özgür Çoğulu
Muhsi̇n Özgür Çoğulu
ADAsude Durmaz
Asude Durmaz
ZCZehra Cengi̇sİz
Zehra Cengi̇sİz
FYFethi̇yE Ferda Yilmaz
Fethi̇yE Ferda Yilmaz
MDMustafa Şevket Dereli̇
Mustafa Şevket Dereli̇
By CENGİZ ÇAVUŞOĞLU, MUHSİN ÖZGÜR ÇOĞULU, ASUDE DURMAZ, et al., Published on 01/01/22

12 February 2021 in Turkish Thoracic Journal
Verified
Journal Article
Closed access
RKRahime Aydın Kayalı
Rahime Aydın Kayalı
SÖSerir Aktoğu Özkan
Serir Aktoğu Özkan
CBCan Biçmen
Can Biçmen
OEOnur Fevzi Erer
Onur Fevzi Erer
Fluoroquinolones,drug resistance,tuberculosis

25 April 2022 in Mikrobiyoloji Bulteni
Verified
Journal Article
Closed access
DÖDidem Özgür
Didem Özgür
SÜSeda Tezcan Ülger
Seda Tezcan Ülger
MKMediha Begüm Kayar
Mediha Begüm Kayar
CBCan Biçmen
Can Biçmen
AAAhmet Aslantürk
Ahmet Aslantürk
GAGonul Aslan
Gonul Aslan
Pyrazinamide (PZA) is one of the first-line anti-tuberculous drugs used in the treatment of tuberculosis (TB). Considering the ability of PZA to shorten the treatment period from 9-12 months to six months by eliminating persistent bacilli, it appears to be an important cornerstone of TB therapy. While the main mechanism causing the PZA resistance is pncA mutations at a rate of 70-97%, it has been determined that rpsA and panD mutations can also cause resistance. In this study, we aimed to investigate the pncA, rpsA and panD gene mutations, the efficiency of the pyrazinamidase (PZAse) enzyme test in determining PZA resistance, the drug susceptibility and their families in PZA-resistant Mycobacterium tuberculosis iso-lates. Totally 46 PZA resistant M.tuberculosis isolates were included in the study. The pncA, rpsA and panDmutations caused by PZA resistance were investigated by in-house PCR followed by DNA sequencing method. Drug susceptibility was determined with Bactec MGIT 960 (Becton Dickinson, USA) system, the presence of PZAse was evaluated by colorimetric PZAse enzyme assay and thefamilies were deter-mined by the spoligotyping method. Of the 46 PZA-resistant isolates, 24 (52.2%) were identified as PZA monoresistant, 11 (23.9%) multidrug resistant (MDR)-TB and 11 (23.9%) poly drug resistant (PDR)-TB. Gene mutations associated with resistance were detected in 73.9% (34) of PZA-resistant M.tuberculosisisolates. The pncA, rpsA and panD mutations were found in 71.7% (33), 28.2% (12) and 4.3% (2) of the isolates, respectively. The coexistence of pncA/rpsA and pncA/panD gene mutations were determined in 12 and two isolates, respectively. The pncA gene mutations were observed in 3 (33.3%) of 9 (19.6%) isolates whose enzyme presence was detected by the colorimetric PZAse test.In the pncA gene, eight different point mutations in the form of missense mutation;A226C (27.3%), A152C (24.2%), C169G (21.2%) A422C (9.1%), G145A (6.1%), A29G (6.1%), A424G (3%) and T464G (3%) were detected. In the rpsA gene, A636C (42.9%) silent and G1318A (42.9%) missense mutations and in the panD gene, C66G (50%) nonsense and A145G (50%) missense mutations were the most common mutations detected. As a result of genotyping of PZA resistant isolates, the most common genotypes were found in T1 cluster with 17 (36.9%) isolates; followed by the families of Beijing with 7 (15.2%) isolates, H3 with 6 (13%) isolates, TUR with 5 (10.9%) isolates, and LAM 9with 4 (8.7%) isolates, respectively. In addition, 2 (4.3%) isolates belonging to the ORPHAN family and one isolate belonging to each of LAM TUR, LAM 2, LAM 7, T2, T5-RUS1 families were identified. Our study is the first to investigate all pncA, rpsA and panD gene mutations that have been found to cause PZA resistance in Turkiye. Epidemiological studies on PZA resistance will make important contributions to the determination of resistance mechanism and the development of methods that will provide rapid diagnosis for the detection of resistance.

30 September 2025 in Journal of Basic and Clinical Health Sciences
Verified
Journal Article
Closed access
TKTuba Tatlı Kiş
Tuba Tatlı Kiş
SYSüleyman Yıldırım
Süleyman Yıldırım
FTFeride Tamay Tatlı
Feride Tamay Tatlı
MOMuhammed Mehdi Ok
Muhammed Mehdi Ok
CBCan Biçmen
Can Biçmen
CKCenk Kıraklı
Cenk Kıraklı
Purpose: Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are significant public health problems worldwide. The aim of this study was to determine the etiological pathogens, susceptibility distribution, and parameters that may indicate poor prognosis in patients diagnosed with HAP/VAP and followed up in the intensive care unit (ICU). Materyal-Metod: This study was designed as a retrospective cohort study. Demographic characteristics, causative microorganisms, susceptibility profiles of these pathogens, and 28-day mortality data (all-cause) of patients diagnosed with HAP and VAP who were hospitalized in the ICU were retrospectively reviewed from patient files. At the end of the 28-day period, patients were divided into survivor and non-survivor groups based on their survival status. Clinical parameters were compared between the two groups. Results: This study included 142 patients diagnosed with HAP who were followed up at ICU. Of these, 102 (71.8%) patients were diagnosed with ventilator-associated pneumonia (VAP). The median age of the cohort was 72 years (IQR: 65–79), and 73.9% were male. The frequency of concomitant malignancy (43.0% vs 25.0%, p=0.029), WBC values at the onset of pneumonia [median 15.2 (IQR: 9.8–20.9) vs 11.9 (IQR: 8.6–14.4), p=0.010], procalcitonin levels [median 0.9 [(IQR: 0.3–5.3) vs 0.3 (IQR: 0.1–1.4) p=0.003], and the frequency of bacteremia secondary to pneumonia (39.5% vs 8.9% p

30 March 2023 in Thoracic Research and Practice
Verified
Journal Article
Open access
OKOnur Karaman
Onur Karaman
YVYelda Varol
Yelda Varol
TATulay Akarca
Tulay Akarca
ÇAÇağrı Atasoy
Çağrı Atasoy
CBCan Bicmen
Can Bicmen
MDMustafa Sevket Dereli
Mustafa Sevket Dereli
Tuberculosis,treatment,mortality,multidrug-resistant tuberculosis

1 January 2024 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
TKTuba Tatlı Kiş
Tuba Tatlı Kiş
CBCan Biçmen
Can Biçmen
SYSuleyman Yıldırım
Suleyman Yıldırım
OEOzlem Ediboğlu
Ozlem Ediboğlu
FYFatma Sebnem Yıldız
Fatma Sebnem Yıldız
CKCenk Kıraklı
Cenk Kıraklı
OBJECTIVE: In this study, we aimed to assess the effect of the BioFire FilmArray Blood Culture Identification 2 panel on agent identification and antimicrobial stewardship in patients with a critical state of sepsis secondary to bloodstream infection.